An integrated biocatalysis-crystallization concept was developed for the continuous amine transaminase-catalyzed synthesis of (S)-1-(3-methoxyphenyl)ethylamine, which is a valuable intermediate for the synthesis of rivastigmine, a highly potent drug for the treatment of early stage Alzheimer’s disease. The three-part vessel system developed for this purpose consists of a membrane reactor for the continuous synthesis of the product amine, a saturator vessel for the continuous supply of the amine donor isopropylammonium and the precipitating reagent 3,3-diphenylpropionate and a crystallizer in which the product amine can continuously precipitate as (S)-1-(3-methoxyphenyl)ethylammonium-3,3-diphenylpropionate.

The solid‐state structure and Raman spectrum of Wannagat's mercurane, Hg[N(SiMe3)2]2 (1), are reported. Crystals were grown from the pure substance by slow cooling to –24 °C. Compound 1 crystallizes in the monoclinic space group P21/c as discrete monomers, which do not display intermolecular mercurophilic interactions. The molecular structure features a nearly linear N–Hg–N scaffold, while the (Me3Si)2N groups are in a staggered conformation with a dihedral angle of 58.3° (average) to each other. This can be attributed to intramolecular dispersion interactions according to DFT calculations.